Abstracts tagged "DMARDs"

Abstract Number: 1676 • 2015 ACR/ARHP Annual Meeting
Systematic Review and Network Meta-Analysis of Combination Treatments in Disease Modifying Anti-Rheumatic Drug Experienced Patients with Severe Rheumatoid Arthritis: Analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update
Michelle E. Orme¹, Charles Hawes² and Stephen A. Mitchell³, ¹ICERA consulting UK, Swindon, United Kingdom, ²Pfizer UK, Surrey, United Kingdom, ³Abacus International UK, Bicester, United Kingdom
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (DMARDs) in combination with conventional DMARDs provide patients with severe rheumatoid arthritis (RA) and an inadequate response to conventional DMARDs…
Abstract Number: 2790 • 2015 ACR/ARHP Annual Meeting
Leflunomide/Hydroxychoroquine Combination Treatment Additively Inhibits T Cell Receptor/Toll-like Receptor 9-Triggered Th1 and Th17 Cytokine Secretion
E.H.M. van der Heijden^1,2, S.A.Y. Hartgring¹, S. Hiddingh¹, A.A. Kruize², T.R.D.J. Radstake^1,3 and J.A.G. van Roon¹, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Primary Sjögren’s Syndrome (pSS) is a systemic auto-immune disease, leading to an exocrinopathy of mainly salivary and lachrymal glands. T- and B-cell-driven immunity is…
Abstract Number: 2026 • 2014 ACR/ARHP Annual Meeting
Treatment Delays and Worse Outcomes Associated with Lower Socioeconomic Status in Rheumatoid Arthritis
Emily Molina¹, Jose Felix Restrepo², Inmaculada del Rincon¹, Daniel Battafarano³ and Agustin Escalante⁴, ¹Rheumatology, University of Texas Health Science Center, San Antonio, TX, ²Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, ⁴Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Treatment Delays and Worse Outcomes Associated with Low Socioeconomic Status in Rheumatoid ArthritisBackground/Purpose: Prompt and routine care in rheumatoid arthritis (RA) is critical for best…
Abstract Number: 493 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD
C. Charles-Schoeman¹, Gerd Burmester², P. Nash³, C.a.F. Zerbini⁴, S. Anway⁵, K. Kwok⁶, T. Hendrikx⁷, E. Bananis⁸ and Roy Fleischmann⁹, ¹University of California, Los Angeles, CA, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁴Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer BV, Capelle aan den IJssel, Netherlands, ⁸Pfizer Inc, Collegeville, PA, ⁹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the efficacy and safety of tofacitinib 5…
Abstract Number: 2973 • 2014 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Score As a Predictor of Radiographic Progression in a Registry of Patients with Rheumatoid Arthritis
Eric H. Sasso¹, George Wu², CC Hwang², Michael E. Weinblatt³, Nancy A. Shadick⁴, Claire Alexander⁵ and Oscar Segurado¹, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ³Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Clinical Operations, Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose This study evaluated the association between baseline disease activity, as assessed with the multi-biomarker disease activity (MBDA) blood test, CRP or clinical measures, and…
Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
Abstract Number: 461 • 2014 ACR/ARHP Annual Meeting
Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs
P. Bird¹, W. Bensen², B. El-Zorkany³, J. Kaine⁴, B.H. Manapat-Reyes⁵, V. Pascual-Ramos⁶, D. Witcombe⁷, A. Anisfeld⁸, K. Soma⁹, R. Zhang⁹ and K. Thirunavukkarasu⁷, ¹Combined Rheumatology Practice, Sydney, Australia, ²St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada, ³Department of Rheumatology, Cairo University, Cairo, Egypt, ⁴Sarasota Arthritis Research Center, Sarasota, FL, ⁵Section of Rheumatology, Department of Medicine, University of the Philippines - Philippine General Hospital, Manila, Philippines, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷Pfizer Australia, Sydney, Australia, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib has been approved in the US and other countries at the recommended dose 5 mg BID in patients (pts) with rheumatoid arthritis (RA) and…
Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman² and Vinod Chandran², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
Abstract Number: 1871 • 2014 ACR/ARHP Annual Meeting
Puberty and Disease Activity in JIA
Philomine A. van Pelt¹, Aike.a. Kruize², Anita C.S. Hokken-Koelega³, Radboud JEM Dolhain⁴, Johannes WJ Bijlsma⁵ and Nico M. Wulffraat⁶, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatrics, Subdivision of Endocrinology, Erasmus Medical Center- Sophia Children's Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁵Dept of Rheumatology and Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁶Paediatric Immunology, University Medical Centre Utrecht, Utrecht, Netherlands
Background/Purpose Delayed puberty and decreased final length has been reported in chronic diseases like Crohn's disease and JIA with a disease onset at prepubertal age.…
Abstract Number: 478 • 2014 ACR/ARHP Annual Meeting
Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study
Christos E. Lampropoulos¹, Philippos Orfanos², Vasiliki-Kalliopi Bournia³, Theofilos P. Karatsourakis⁴, Clio P. Mavragani⁵, Dimitrios Pikazis⁴, Menelaos N. Manoussakis⁶, Athanasios G. Tzioufas⁴, Haralampos M. Moutsopoulos⁷ and Panayiotis G. Vlachoyiannopoulos³, ¹Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ²Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National University of Athens, Athens, Greece, ³First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁵Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁶Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ⁷Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease with joint destruction and permanent disability. Biologic agents (BAs) offer a better outcome when disease is…
Abstract Number: 2902 • 2014 ACR/ARHP Annual Meeting
The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care
Kirsten Minden¹, Jens Klotsche², Martina Niewerth², Angela Zink³ and Gerd Horneff⁴, ¹Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ²Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ³German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany
Background/Purpose A minority of patients with polyarticular JIA enter adulthood in drug free remission. Thus, patients are in need of care beyond adolescence. There is…
Abstract Number: 1527 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison
Laura Sawyer¹, Stacey Chang¹, Alex Diamantopoulos² and Fred Dejonckheere³, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: To date, no head-to-head trials have been conducted comparing the efficacy of biologic treatments for early active rheumatoid arthritis (ERA). Here, we evaluated the…
Abstract Number: 477 • 2014 ACR/ARHP Annual Meeting
Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials
Richard Conway¹, Candice Low², Robert J. Coughlan¹, Martin O'Donnell³ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Medicine, St. James Hospital, Dublin, Ireland, ³Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose Leflunomide is an effective treatment for rheumatoid arthritis. An association between pulmonary adverse events, in particular interstitial lung disease, and leflunomide use has been…
Abstract Number: 2832 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study
Elisabeth Lie^1,2, Lars Erik Kristensen³, Helena Forsblad-d'Elia¹, Johan Askling⁴ and Lennart T. Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose For rheumatoid arthritis it is well established that co-medication (co-med) with methotrexate (MTX) increases the efficacy and drug survival of TNF inhibitors (TNFi), while…
Abstract Number: 1488 • 2014 ACR/ARHP Annual Meeting
Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~
Yasuhide Kanayama¹, Toshihisa Kojima², Atsushi Kaneko³, Yuji Hirano⁴, Nobunori Takahashi², Shinya Hirabara⁴ and Naoki Ishiguro², ¹Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan
Background/Purpose Iguratimod (IGU) is a small-molecule antirheumatic drug that was approved in Japan in September 2012. IGU suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].